Alphavax

Alphavax focuses on developing innovative vaccines utilizing proprietary RNA particle technology, targeting both anti-infective and anti-cancer applications with a strong emphasis on cancer immunotherapy. Alphavax is a biotechnology company based in the US, specializing in vaccine development. The company was formed through the initiative of its founders and has not undergone significant pivots or changes in business operations. It has conducted multiple funding rounds, with the most recent being a Series E round where it raised USD 12.

00 mn on January 11, 2007, bringing the total amount raised to USD 12. 00 mn with a current company valuation of USD 49. 40 mn. AlphaVax Inc.

specializes in the development of innovative vaccines utilizing its proprietary RNA particle alphavaccine vector platform technology. The company focuses on both anti-infective and anti-cancer vaccines, with a notable emphasis on cancer immunotherapy. Their product offerings include a portfolio of seven vaccine candidates designed to prevent infectious diseases and treat various types of cancers, such as breast and gastrointestinal cancers. AlphaVax has achieved significant milestones, having conducted multiple Phase 1 clinical trials evaluating candidates targeting human cytomegalovirus, influenza A virus, prostate cancer, and HIV-1, demonstrating the broad applicability of their technology.

The primary end users of these vaccines are patients requiring preventive measures against infectious diseases and therapies for cancer treatment, targeting healthcare institutions and oncology clinics in North America, Europe, and other regions where these diseases are prevalent. AlphaVax Inc. operates through strategic partnerships and collaborations to commercialize its proprietary vaccine technology. The company's revenue model is primarily based on out-licensing their alphavaccine technology for specific disease applications, facilitating revenue generation through agreements with external partners focused on anti-infective vaccines.

These partnerships involve structured transactions in which AlphaVax licenses its technology to third parties, enabling them to develop and commercialize vaccines based on the alphavaccine platform. Revenue is derived from upfront licensing fees, milestone payments, and potential royalties on sales from the resulting products. Given the nature of the biotechnology sector, these transactions typically cater to pharmaceutical companies and research organizations looking to leverage advanced vaccine technologies in their product pipelines. Alphavax plans to enhance its product portfolio by designing new vaccines leveraging its innovative RNA technology, with specific launch dates and product details to be determined in future development phases.

The company aims to expand into global markets, particularly targeting Europe and Asia by 2025. Recent funding from the Series E round will support these initiatives, providing capital for research and development efforts aimed at advancing new vaccine candidates and establishing strategic partnerships in international markets.